Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Department of Communications 2016 in the news \\\ September – December Selected MEDIA HIGHLIGHTS A BRA M SON C ANC ER C ENT E R Penn Medicine News Release POST Online Media The New York Times Men's Journal Reuters via Fox News CBS News Yahoo! News Philadelphia Inquirer HemOnc Today Homecare.co.uk Health Medicine Network Patch NJ.com Medical Xpress Science Blog Medical News Today HealthDay Medindia DocGuide.com MedicalResearch. com \ S pecial F eature \ Dementia Risk Identified For Men Treated For Prostate Cancer A new study by Penn Medicine and Stanford researchers found that a type of hormone therapy called androgen deprivation therapy may double the risk of developing dementia. “We thought that these treatments, because they lower testosterone, could negatively impact neurological health globally and we were interested in seeing if ADT is linked with dementia,” said Kevin T. Nead, MD, MPhil, a resident in Radiation Oncology and lead author of the study. Early Surgery Ups Mortality Risk for Some Endometrial Cancer Patients An article from HealthDay's Physician's Briefing reports on recent research showing that for patients diagnosed with endometrial cancer, surgery within the first two weeks of diagnosis is associated with increased risk of mortality. Senior author, David I. Shalowitz, MD, a fellow in Gynecologic Oncology, was quoted. Physician’s Briefing OncLive Making Tumors Glow Shows Promise for Cancer Treatment Research led by John Y.K. Lee, MD, and Sunil Singhal, MD, both associate professors of Surgery, about an experimental cancer imaging tool that makes tumors glow brightly during surgery was covered by Lancaster Online. Lancaster Online Beating Breast Cancer But Still Paying a Price HealthDay reported on new research showing that 92 percent of long-term breast cancer survivors report at least three untreated symptoms for which they need assistance. When you extrapolate these results to the larger population of survivors, “it gets a lot worse very quickly,” said lead author Steven Palmer, PhD, a research scientist at the Abramson Cancer Center. “You end up talking about hundreds of thousands of people with unmet needs in the community.” Penn Medicine News Release HealthDay S E L E C T E D M E D I A H I G H L I G H T S \ \ \ IN THE NEWS \ \ \ September – December 2016 \ \ \ facebook.com/pennmed \ \ \ @PennMedNews \ \ \ news.pennmedicine.org/blog/ Woman Travels from Germany to Reunite with NJ Man After Bone Marrow Transplant Jack Zefutie of East Windsor, NJ and Lisa Froemel of Germany were once complete strangers, but Jack said her selflessness in donating bone marrow two-and-a-half years ago kept him alive. Lisa recently made a trip to Philadelphia and Jack introduced her to his care team at the Hospital of the University of Pennsylvania. Selina Luger, MD, director of the Leukemia Program, was quoted. 6ABC Philadelphia Inquirer The CRISPR Pioneers Carl June, MD, a professor of Pathology and Laboratory Medicine and director of the Center for Cellular Immunotherapies, was named among a group of scientists doing pioneering work using CRISPR gene-editing technology as the fifth place in Time magazine’s annual Person of the Year issue. June and Edward Stadtmauer, MD, chief of Hematologic Malignancies and a professor of HematologyOncology in the Abramson Cancer Center, are poised to launch the nation’s first human trial using CRISPR for the treatment of cancer, an effort the magazine notes may bear out hope for CRISPR’s therapeutic potential for diseases of all kinds. Time Study Raises Questions About NLR as Bladder Cancer Biomarker A Penn study led by Eric Ojerholm, MD, a resident in Radiation Oncology, challenges previous research about a blood exam that has shown promise in predicting how bladder cancer will progress and what treatments will be most effective for a given patient. Penn Medicine News Release MedicalResearch. com HealthMedicineNet. com Study Shows Posttransplant Strategies Equivalent in Myeloma Edward Stadtmauer, MD, chief of Hematologic Malignancies and a professor of Hematology-Oncology in the Abramson Cancer Center, led a randomized trial comparing different treatment strategies following stem cell transplant for multiple myeloma. Selina Luger, MD, a professor HematologyOncology and director of the ACC’s Leukemia program, is also quoted in coverage about the study, which was presented during the annual meeting of the American Society of Hematology this week. MedPage Today OncLive 1 Patient, 7 Tumors and 100 Billion Cells Equal 1 Striking Recovery Carl June, MD, a professor of Pathology and Laboratory Medicine and director of the Center for Cellular Immunotherapies, wrote an editorial accompanying a New England Journal of Medicine paper about a T-cell transfer treatment, which was the first to successfully target KRAS, a common cancer mutation. If replicable, June said, the approach has great potential for patients with pancreatic and colorectal cancers. The New York Times Philadelphia Inquirer Stability of Exhausted T Cells Limits Durability of Cancer Checkpoint Drugs Cancer Research UK featured a study led by John Wherry, PhD, director of the Institute for Immunology and a professor of Microbiology, which found that reinvigorating exhausted T cells in mice using a PDL1 blockade caused very few T memory cells to develop. After the blockade, re-invigorated T cells became re-exhausted if antigen from the virus remained high, and failed to become memory T cells when the virus was cleared. Penn Medicine News Release AJMC.com Cancer Research UK S E L E C T E D M E D I A H I G H L I G H T S \ \ \ IN THE NEWS \ \ \ September – December 2016 \ \ \ facebook.com/pennmed \ \ \ @PennMedNews \ \ \ news.pennmedicine.org/blog/ CRISPR Gene-Editing Tested in a Person for the First Time Carl June, MD, a professor of Pathology and Laboratory Medicine and director of Translational Research in the Abramson Cancer Center, was quoted in stories detailing a Chinese team's first use of CRISPR gene editing technology to treat a cancer patient. Nature MIT Tech Review Daily Mail Popular Mechanics Smithsonian magazine Wall Street Daily US News & World Report Telegraph (UK) CARs For Cancer Driving Toward Market Researchers from Penn Medicine and the Children’s Hospital of Philadelphia presented the latest findings of trials of CAR T cells for cancer during this week’s annual meeting of the American Society of Hematology in San Diego. Results included the first look at data from the global multisite trial of the therapy for pediatric acute lymphoblastic leukemia patients. Penn Medicine News Release OncLive Reuters Medscape (log on required) Cure Endpoints Bloomberg Fierce Biotech Xconomy Helpful Advice for Patients from an Oncology Nurse Kristen Maloney, MSN, RN, an oncology nurse manager at the Hospital of the University of Pennsylvania, offers tips for cancer patients. Among other advice, Maloney said it’s important to get to know your care team, make communication a priority, and understand your medications. Philadelphia Inquirer Preventative Antibiotics May Prevent C. diff Infection for Some Blood-cancer Patients Research led by Alex Ganetsky, PharmD, a clinical pharmacist in the Blood and Bone Marrow Transplantation Program, and David Porter, MD, director of the Blood and Marrow Transplantation Program, shows C. diff may be preventable in allogeneic stem cell transplant patients. Penn Medicine News Release Philadelphia Inquirer CAR T Cells: Progress, but Questions Remain A HemOnc Today article examines progress in the field of CAR T cell research to treat blood cancers. Stephan Grupp, MD, PhD, director of the cancer immunotherapy program and director of translational research for the Center for Childhood Cancer at Children’s Hospital of Philadelphia and a professor of Pediatrics at Penn, and David Porter, MD, a professor of Hematology-Oncology and director of Blood and Marrow Transplantation in Penn’s Abramson Cancer Center, are highlighted. HemOnc Today Cancer Survivor Defies the Odds, Serves Up Thanksgiving Meals The Abramson Cancer Center partnered with HEADstrong to serve Thanksgiving Dinner to patients. The effort was led by Joseph Cliffor, a former patient who was treated for leukemia at the Abramson Cancer Center in 2008. Delaware County Daily Times S E L E C T E D M E D I A H I G H L I G H T S \ \ \ IN THE NEWS \ \ \ September – December 2016 \ \ \ facebook.com/pennmed \ \ \ @PennMedNews \ \ \ news.pennmedicine.org/blog/ New Tricks in Canine Cancer Research May Improve Treatments for Humans, Too A Washington Post article profiled the work of Penn Vet and Penn Medicine researchers in the burgeoning field called “comparative oncology,” which focuses on finding new ways to treat cancer in pets, mostly dogs, in an effort to develop innovative treatments for people and animals. Washington Post In the War Against Cancer, Modesty is Not an Ally The Toronto Star profiled Steven Narod, MD, FRCPC, FRSC, director of the Familial Breast Cancer Research Unit and a senior scientist at the Women’s College Hospital in Toronto, whose seminal work on BRAC 1 and 2 breast cancer genes earned him this year's Basser Global Prize. Narod is the first Canadian to receive the annual recognition from The Basser Center for BRCA at Penn’s Abramson Cancer Center. Toronto Star Pricey New Treatment Roils Issues Of How To Treat Prostate Cancer High-intensity focused ultrasound, often not covered by insurance, leads to discussions about which patients benefit in the real world, reported Kaiser Health News. Justin Bekelman, MD, an associate professor of Radiation Oncology, was quoted. Kaiser Health News Gene Pioneers Share Philly Science Award for CRISPR The Philadelphia Inquirer reported Carl June, MD, a professor of Immunotherapy in Pathology and Laboratory Medicine, will receive a John Scott Medal, an annual award that has been given since 1822. Philadelphia Inquirer Treatment Not Tied to Prostate Cancer Survival In the first study to compare active monitoring, surgery and radiation for prostate cancer, researchers found no differences in death rates. Additional results found that contrary to many previous studies, radiation therapy had a better side effect profile than surgery in terms of urinary and sexual dysfunction. Neha Vapiwala, MD, an associate professor of Radiation Oncology who was not involved in the research, was quoted. Philadelphia Inquirer Penn Physician, Patient Support Free to Breathe Event for Lung Cancer Awareness Tracey L. Evans, MD, an associate professor of clinical medicine in Hematology-Oncology, appeared on Good Day Philadelphia and with NBC10’s Vai Sikahema, along with two of her patients, to talk about the 11th Annual Free to Breathe Run and Walk to raise awareness for lung cancer. Good Day Philadelphia NBC10 Liquid Biopsy Can Noninvasively Detect, Monitor NSCLC For patients with advanced lung cancer, a non-invasive liquid biopsy may be a more effective and suitable alternative to the gold standard tissue biopsy to detect clinically relevant mutations and help guide their course of treatment, according to a recent Penn study. Erica L. Carpenter, PhD, MBA, director of the Circulating Tumor Material Laboratory, and Jeffrey C. Thompson, MD, a Pulmonary, Allergy and Critical Care medicine physican with Penn, were quoted in HemOnc Today. Penn Medicine News Release HemOnc Today Oncology Times Real World Health Care Genetic Engineering and Biotechnology News MedDevice Online MedResearch.com Philadelphia Inquirer S E L E C T E D M E D I A H I G H L I G H T S \ \ \ IN THE NEWS \ \ \ September – December 2016 \ \ \ facebook.com/pennmed \ \ \ @PennMedNews \ \ \ news.pennmedicine.org/blog/ Tech Giant Sean Parker Launches Penn’s Cancer Immunotherapy Center Sean Parker, the Napster founder and former Facebook president turned philanthropist, visited Penn to celebrate the launch of Penn’s Parker Institute for Cancer Immunotherapy. Parker was joined by scientists including the center’s leader, cellular therapy pioneer Carl June, MD, a professor of Immunotherapy in Pathology and Laboratory Medicine. ABC News Chief Health and Medical Editor Richard Besser, MD, a Perelman School of Medicine graduate, moderated a panel discussion during the event. Philadelphia Inquirer 6ABC Philly Voice Adding PD-1 Inhibition to Chemotherapy Boosts Response in Untreated NSCLC Corey Langer, MD, director of Thoracic Surgery, was featured in OncLive for his research showing the addition of pembrolizumab (Keytruda) to frontline platinum-based chemotherapy for advanced nonsmall cell lung cancer almost doubled the response rate compared with chemotherapy alone. OncLive Abramson Cancer Center: Philly Fights Cancer Round 2 More than a thousand people attended last year’s Philly Fights Cancer fundraiser for the Abramson Cancer Center. Lionel Richie, Jennifer Hudson, and Tig Notaro performed at the event, which raise $5.4 million to support research and clinical trials. Philadelphia Inquirer Fox 29 Philadelphia magazine Philly.com Metro NBC10 The Role of Prognostic Signatures Based on CCP in Lung Cancer Corey Langer, MD, director of Thoracic Surgery, participated in a Q & A about the use of data to determine risk in patients with early-stage non-small stage lung cancer. Targeted Oncology Are You Diagnosed with DCIS? Carmen E. Guerra, MD, associate director for diversity and outreach at the Abramson Cancer Center, was featured in an El Diario article about non-invasive breast cancer. El Diario (1) El Diario (2) Breast Cancer Runs in This Family, but So Do Strength and Love The Philadelphia Inquirer profiled Penn patient Maria Gentile, who has known she has a 50 percent chance of carrying the BRCA mutation for nearly 10 years. The genetic mutation is also carried by her mother and other family members, several of whom also receive care at the Basser Center for BRCA at Penn's Abramson Cancer Center. Angela Bradbury, MD, an assistant professor of Hematology/ Oncology and Medical Ethics & Health Policy, was quoted on recent research showing that young women from families with a history of breast cancer do not have higher rates of psychological problems such as depression and anxiety. Philadelphia Inquirer S E L E C T E D M E D I A H I G H L I G H T S \ \ \ IN THE NEWS \ \ \ September – December 2016 \ \ \ facebook.com/pennmed \ \ \ @PennMedNews \ \ \ news.pennmedicine.org/blog/ What to Expect at the 2016 ‘FFANY Shoes on Sale’ Gala In a preview of the 23rd annual QVC Presents “FFANY Shoes on Sale” fundraising gala, Footwear News reported on the nine beneficiaries, which includes the 2-Prevent Breast Cancer Translational Center of Excellence at Penn's Abramson Cancer Center. Angela DeMichele, MD, MSCE, co-leader of Penn's Breast Cancer Research Program, said funding received from Shoes on Sale over the years “has been instrumental” in developing the research center. Footwear News Merck Tops as Lung Cancer Treatment Moves Past Chemotherapy Corey Langer, MD, director of Thoracic Oncology, was quoted in a Bloomberg report that lung cancer treatment is moving beyond chemotherapy, with Merck setting the pace in a new category of therapies that harness the body’s immune system to fight tumors. Bloomberg First-line Pembrolizumab Plus Chemotherapy Improves Response Rates Corey Langer, MD, director of Thoracic Oncology, was the keynote speaker at the European Society for Medical Oncology Congress over the weekend. He presented his findings on the addition of pembrolizumab to standard first-line chemotherapy. HemOnc Today Germline Mutations Uncovered Through Tumor Sequencing Present Challenges for Providers Clinicians and genetic counselors are coming up with triage strategies for cancer cases in which medically actionable germline mutations are suspected. Jennifer Morrissette, PhD, clinical director of the Center for Personalized Diagnostics, and genetic counselor Dana Farengo Clark commented in Genomeweb. Genomeweb The Changing Field of Lung Cancer Care From promising new therapies to risk prediction, the field of lung cancer care is rapidly evolving. Corey J. Langer, MD, a professor of Hematology/Oncology and director of the Thoracic Oncology Program in Penn’s Abramson Cancer Center, was quoted on the latest developments. CURE Special Guest Bethenny Frankel Shines at Evening of Giving to Benefit Abramson The King of Prussia Mall opened its doors after-hours for a special benefit for Penn Medicine’s Abramson Cancer Center. The Town Dish covered the event. The Town Dish Novel Pancreatic Cancer Trial Aims to Give Patients More Options A $35 million bid to test precision therapy for pancreatic cancer will let patients shift to a new experimental treatment if the first fails. Robert Vonderheide, MD, DPhil, associate director for Translational Research at the Abramson Cancer Center, was interviewed as an expert. STAT S E L E C T E D M E D I A H I G H L I G H T S \ \ \ IN THE NEWS \ \ \ September – December 2016 \ \ \ facebook.com/pennmed \ \ \ @PennMedNews \ \ \ news.pennmedicine.org/blog/ U.S. University Doing Clinical Studies on Autophagy Ravi Amaravadi, MD, an associate professor of Medical Oncology, appeared as a guest on Radio Times to discuss this year's Nobel Prizes and how they are influencing his own research in autophagy. Radio Times Knowing Their Breast Cancer Risk May Empower Teens A new study from researchers at Penn shows that knowing they have a family history of breast cancer or a high-risk gene mutation doesn't lead to increased anxiety or depression in teen girls. Lead author Angela Bradbury, MD, an assistant professor of Hematology/Oncology and Medical Ethics and Health Policy, was quoted. Health Day via Philadelphia Inquirer Couture for a Cure A runway show last week at the King of Prussia Mall’s Neiman Marcus, featuring fall fashions from renowned fashion designers Badgley Mischka, benefitted the Abramson Cancer Center’s lymphoma program. 6ABC Physicians and Physicists Join Forces to Fight Pancreatic Cancer Jeffrey Drebin, MD, PhD, chair of the department of Surgery, was quoted in a Wall Street Journal article about a new Stand Up to Cancer “convergence” team he is part of which brings physicians and physicists with diverse expertise together to develop new strategies to attack pancreatic cancer, one of medicine’s most lethal malignancies. Wall Street Journal Cancer-Risk Genetic Testing Reports Can Vary From Lab to Lab Testing for gene mutations linked to cancer risk may guide how a patient is treated, but the determination of whether a mutation is dangerous or benign can vary from lab to lab, according to a recent study. “As we do testing on more and more genes that we didn’t use to test for there is more uncertainty,” said senior author Susan M. Domchek, MD, executive director of the Basser Center for BRCA at Penn's Abramson Cancer Center. Reuters Melanoma Patient's Legacy Lives on in $450,000 Gift to Penn Research The Philadelphia Inquirer's Diagnosis: Cancer blog reported on an event earlier this week, in which the Tara Miller Melanoma presented Penn Medicine's Abramson Cancer Center with a check for $450,000, bringing the total it has donated to Penn to $1.1 million. The foundation honors Tara Miller who created the foundation before passing away from Melanoma in 2014. Lynn Schuchter, MD, chief of Hematology/Oncology and Tara’s medical oncologist, was quoted. Philadelphia Inquirer PHL17 S E L E C T E D M E D I A H I G H L I G H T S \ \ \ IN THE NEWS \ \ \ September – December 2016 \ \ \ facebook.com/pennmed \ \ \ @PennMedNews \ \ \ news.pennmedicine.org/blog/ Finding Moments of "Extraordinary Happiness" In a piece posted to the Philadelphia Inquirer's Diagnosis: Cancer blog, Penn patient Diego Luzuriaga talked about finding moments of happiness after being diagnosed with metastatic cancer. Luzuriaga was diagnosed with metastatic Nasopharyngeal cancer in 2015. Today, he is part of the workshop Writing for Life at Penn Medicine's Abramson Cancer Center. Diagnosis: Cancer blog “Moonshot” Group Has 10 Ways to Speed Up Search for Cancer Cures Chi Dang, MD, PhD, director of the Abramson Cancer Center, was quoted in a Philadelphia Inquirer article detailing the new recommendations in a report from Vice President Joe Biden’s cancer “moonshot” blue ribbon panel. Breaking down barriers is crucial to speeding up breakthroughs, said Dang, who serves on the panel. “How do you get the full picture? By shifting the culture of how we do science to collect the right kind of information and be willing to share it,” he said. Philadelphia Inquirer Dr. DeMichele on Importance of Neoadjuvant Care in HER2+ Breast Cancer In a video interview with OncLive, Angela DeMichele, MD, MSCE, a professor of Medicine & Epidemiology and co-leader of the Breast Cancer Program at the Abramson Cancer Center, discussed the importance of neoadjuvant treatment for patients with HER2-positive breast cancer. Penn Medicine News Release OncLive S E L E C T E D M E D I A H I G H L I G H T S \ \ \ IN THE NEWS \ \ \ September – December 2016 \ \ \ facebook.com/pennmed \ \ \ @PennMedNews \ \ \ news.pennmedicine.org/blog/